Cross-sectional relations of multiple inflammatory biomarkers to peripheral arterial disease: The Framingham Offspring Study

Atherosclerosis

Volumn 203, Issue 2, 2009, Pages 509-514

  Murabito, Joanne M ^a,b   Keyes, Michelle J ^a,c   Guo, Chao Yu ^d   Keaney Jr , John F ^e   Vasan, Ramachandran S ^a,b,f   D'Agostino Sr , Ralph B ^a,c   Benjamin, Emelia J ^a,b,f  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Boston University   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Ankle brachial index; Interleukin 6; Peripheral arterial disease; Tumor necrosis factor receptor 2

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 ANTIGEN; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; OSTEOPROTEGERIN; PADGEM PROTEIN; PHOSPHOLIPASE A2; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; CLINICAL EVALUATION; COMMUNITY SAMPLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATION; INTERMITTENT CLAUDICATION; LEG REVASCULARIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGENY; RISK FACTOR;

AGED; ANKLE BRACHIAL INDEX; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; REGRESSION ANALYSIS; RISK FACTORS;

EID: 62949090529     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.06.031     Document Type: Article

References (34)

1. Selvin E., and Erlinger T.P. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 110 6 (2004) 738-743
2. O'Hare A.M., Katz R., Shlipak M.G., Cushman M., and Newman A.B. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation 113 3 (2006) 388-393
3. Resnick H.E., Lindsay R.S., McDermott M.M., Devereux R.B., Jones K.L., Fabsitz R.R., et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 109 6 (2004) 733-739
4. Murabito J.M., Evans J.C., Larson M.G., Nieto K., Levy D., and Wilson P.W. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med 163 16 (2003) 1939-1942
5. Cesari M., Penninx B.W., Newman A.B., Kritchevsky S.B., Nicklas B.J., Sutton-Tyrrell K., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108 19 (2003) 2317-2322
6. Tuomisto K., Jousilahti P., Sundvall J., Pajunen P., and Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost 95 3 (2006) 511-518
7. Ridker P.M., Stampfer M.J., and Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285 19 (2001) 2481-2485
8. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97 5 (1998) 425-428
9. Khera A., de Lemos J.A., Peshock R.M., Lo H.S., Stanek H.G., Murphy S.A., et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 113 1 (2006) 38-43
10. Hulthe J., Wikstrand J., and Fagerberg B. Relationship between C-reactive protein and intima-media thickness in the carotid and femoral arteries and to antibodies against oxidized low-density lipoprotein in healthy men: the Atherosclerosis and Insulin Resistance (AIR) study. Clin Sci (Lond) 100 4 (2001) 371-378
11. Folsom A.R., Pankow J.S., Tracy R.P., Arnett D.K., Peacock J.M., Hong Y., et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 88 2 (2001) 112-117
12. Tracy R.P., Psaty B.M., Macy E., Bovill E.G., Cushman M., Cornell E.S., et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 17 10 (1997) 2167-2176
13. McDermott M.M., Green D., Greenland P., Liu K., Criqui M.H., Chan C., et al. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol 92 2 (2003) 194-199
14. van dM I., De Maat M.P., Hak A.E., Kiliaan A.J., del Sol A.I., van der Kuip D.A., et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. Stroke 33 12 (2002) 2750-2755
15. Beckman J.A., Preis O., Ridker P.M., and Gerhard-Herman M. Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). Am J Cardiol 96 10 (2005) 1374-1378
16. Tzoulaki I., Murray G.D., Lee A.J., Rumley A., Lowe G.D., and Fowkes F.G. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 112 7 (2005) 976-983
17. Tzoulaki I., Murray G.D., Price J.F., Smith F.B., Lee A.J., Rumley A., et al. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. Am J Epidemiol 163 4 (2006) 334-341
18. Hoogeveen R.C., Morrison A., Boerwinkle E., Miles J.S., Rhodes C.E., Sharrett A.R., et al. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 183 2 (2005) 301-307
19. Murabito J.M., Evans J.C., Nieto K., Larson M.G., Levy D., and Wilson P.W. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 143 6 (2002) 961-965
20. Jefferson A.L., Massaro J.M., Wolf P.A., Seshadri S., Au R., Vasan R.S., et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology 68 13 (2007) 1032-1038
21. Abbott R.D., and McGee D.L. The Framingham Study: An Epidemiologic Investigation of Cardiovascular Disease. Section 37. The Probability of Developing Certain Cardiovascular Diseases in Eight Years at Specified Values of Some Characteristics (1987), National Heart, Lung and Blood Institute, Bethesda, MD
22. Benjamin E.J., Dupuis J., Larson M.G., Lunetta K.L., Booth S.L., Govindaraju D.R., et al. Genome-wide association with select biomarker traits in the Framingham Heart Study. BMC Med Genet 8 Suppl 1 (2007) S11
23. Schnabel R., Larson M.G., Dupuis J., Lunetta K.L., Lipinska I., Meigs J.B., et al. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension (2008)
24. SAS Institute Inc., version 8 (1999), SAS Institute Inc., Cary, NC
25. Signorelli S.S., Mazzarino M.C., Di Pino L., Malaponte G., Porto C., Pennisi G., et al. High circulating levels of cytokines (IL-6 and TNFalpha), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. Vasc Med 8 1 (2003) 15-19
26. Libra M., Signorelli S.S., Bevelacqua Y., Navolanic P.M., Bevelacqua V., Polesel J., et al. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 59 2 (2006) 211-215
27. Tzoulaki I., Murray G.D., Lee A.J., Rumley A., Lowe G.D., and Fowkes F.G. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J 28 3 (2007) 354-362
28. McDermott M.M., Guralnik J.M., Corsi A., Albay M., Macchi C., Bandinelli S., et al. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am Heart J 150 2 (2005) 276-281
29. Spranger J., Kroke A., Mohlig M., Hoffmann K., Bergmann M.M., Ristow M., et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52 3 (2003) 812-817
30. Sesso H.D., Wang L., Buring J.E., Ridker P.M., and Gaziano J.M. Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension 49 2 (2007) 304-310
31. Chandrasekharan U.M., Mavrakis L., Bonfield T.L., Smith J.D., and DiCorleto P.E. Decreased atherosclerosis in mice deficient in tumor necrosis factor-alpha receptor-II (p75). Arterioscler Thromb Vasc Biol 27 3 (2007) e16-e17
32. Chandrasekharan U.M., Siemionow M., Unsal M., Yang L., Poptic E., Bohn J., et al. Tumor necrosis factor alpha (TNF-alpha) receptor-II is required for TNF-alpha-induced leukocyte-endothelial interaction in vivo. Blood 109 5 (2007) 1938-1944
33. Rodriguez C., Alcudia J.F., Martinez-Gonzalez J., Raposo B., Navarro M.A., and Badimon L. Lysyl oxidase (LOX) down-regulation by TNFalpha: a new mechanism underlying TNFalpha-induced endothelial dysfunction. Atherosclerosis (2007)
34. Fiotti N., Giansante C., Ponte E., Delbello C., Calabrese S., Zacchi T., et al. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 145 1 (1999) 51-60